8-K: ImageneBio Highlights IMG-007's Best-in-Class Potential

ImageneBio, Inc. updated its corporate presentation, showcasing IMG-007's promising Phase 1b/2a results in atopic dermatitis and alopecia areata, and outlining its Phase 2b ADAPTIVE study.

Summary

• ImageneBio, Inc. (NASDAQ: IMA) updated its corporate presentation on November 19, 2025, for use with investors and analysts.
• The company is anchored on IMG-007, a differentiated anti-OX40 monoclonal antibody (mAb), currently in a Phase 2b ADAPTIVE study for atopic dermatitis (AD).
• Phase 1b/2a data for IMG-007 in moderate-to-severe AD showed an 87% mean reduction in EASI score from baseline at week 20 after three intravenous (IV) doses.
• EASI-75 (75% improvement in EASI score) was achieved by 54% of participants at weeks 16 and 20, and EASI-90 (90% improvement) by 31% at week 16, maintained through week 24.
• IMG-007 demonstrated a favorable safety profile in AD, with no serious adverse events or treatment-related AEs.
• Proof-of-concept was also shown in alopecia areata (AA), with SALT score improvement and hair regrowth observed.
• The global AD biologics market is estimated at $15 billion in 2025 and is growing year-over-year.
• The company reported $142.6 million in cash and securities at the close of Q3 2025, with a cash runway expected through the end of 2027.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook on IMG-007's clinical progress, safety profile, and market potential, supported by strong Phase 1b/2a data and a solid cash runway. The tone is optimistic, highlighting differentiation and future growth opportunities.

Positives

• IMG-007 showed notable, rapid improvement in AD skin signs, with an 87% mean reduction in EASI score from baseline at week 20.
• High rates of EASI-75 (54%) and EASI-90 (31%) were achieved and maintained through week 24 after only 3 IV doses, indicating durable activity.
• IMG-007 demonstrated a favorable emerging safety profile with no serious adverse events, treatment-related AEs, or infusion reactions in both AD and AA studies.
• Proof-of-concept was established in a second indication, alopecia areata, showing SALT score improvement and hair regrowth, highlighting its 'pipeline-in-a-product' potential.
• IMG-007 is designed with differentiating features: receptor targeting for optimal efficacy, T cell-preserving (silenced ADCC function) for safety and tolerability, and an extended half-life of approximately 5 weeks for patient-friendly dosing.
• The company is well-funded with $142.6 million in cash and securities at Q3 2025, providing a cash runway expected through the end of 2027.

Risks

• Risks associated with the nonclinical and clinical development and regulatory approval of IMG-007, including potential delays in the completion of clinical trials and potential safety and other complications thereof.
• Uncertainty regarding the timing of the availability of data from clinical trials.
• Risks related to the clinical utility, potential differentiation, benefits, and market acceptance of IMG-007.
• The requirement for additional capital to continue to advance the IMG-007 program, which may not be available on favorable terms or at all.
• Challenges in attracting, hiring, and retaining skilled executive officers and employees.
• Inability to protect intellectual property and proprietary technologies.
• Reliance on third parties, contract manufacturers, and contract research organizations.
• Potential adverse effects from other economic, political, business, or competitive factors.
• Risks associated with changes in applicable laws or regulations or government resources and policies.

Future Outlook

The company expects topline data from its IMG-007 AD Phase 2b study in 2027 and anticipates its cash runway to extend through the end of 2027. IMG-007 is positioned as a potential best-in-class OX40 treatment with 'pipeline-in-a-product' growth potential across numerous autoimmune and inflammatory diseases.

Management Comments

• IMG-007 is well positioned to emerge as a best-in-class OX40 treatment.
• We believe OX40 inhibition could be a very effective and novel monotherapy approach and may also have potential in combinations with other agents given its broad, rebalancing (vs. immunosuppressing) mechanism.

Industry Context

The global atopic dermatitis biologics market is estimated at $15 billion in 2025 and growing, yet 30-40% of patients report inadequate disease control even with existing biologics and JAK inhibitors. Only about 15% of biologic-eligible patients receive treatment, indicating a significant unmet need. IMG-007, by targeting OX40, aims to address multiple inflammation-related pathways simultaneously, contrasting with single-pathway inhibitors like dupilumab, potentially offering a broader and more effective treatment for the heterogeneous nature of AD. Its potential in alopecia areata also positions it in a market with high unmet need for safe, durable, and broadly applicable treatments beyond current JAK inhibitors.

Comparison to Industry Standards

• IMG-007 is compared to other OX40/OX40L antagonists, specifically rocatinlimab (Phase 3) and amlitelimab (Phase 3).
• IMG-007 targets the OX40 receptor, while rocatinlimab targets the OX40 ligand, with receptor targeting potentially allowing inhibition in both blood and tissues.
• IMG-007 has an optimized half-life of approximately 5 weeks, which is longer than rocatinlimab (~1.5 weeks) and amlitelimab (~3 weeks), suggesting potential for less frequent dosing.
• IMG-007 is designed to be non-T cell depleting due to its engineered Fc region that silences ADCC function, presented as a safety and tolerability advantage over other potential OX40 therapies.
• No head-to-head trials have been conducted among these therapies, and cross-trial comparisons must be interpreted with caution.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical trial results, expanded market potential, and a clear development pathway for IMG-007.
• Patients (AD & AA): Potential for a new, differentiated, and potentially best-in-class treatment option with improved efficacy, safety, and more convenient dosing schedules compared to existing therapies.
• Healthcare Providers: A new therapeutic option for managing atopic dermatitis and alopecia areata, potentially addressing unmet needs in patient care.
• Employees: Continued employment and potential growth opportunities within a company advancing a promising drug candidate.

Next Steps

• Continue recruiting for the Phase 2b ADAPTIVE trial in North America and Europe.
• More fully characterize the clinical profile of IMG-007, including at a range of drug exposures.
• Understand the role of shortand longer-term treatment.
• Characterize the role of loading doses in driving the magnitude of efficacy and time to onset of effect.
• Evaluate patient-friendly dosing intervals.
• Expect topline data from the IMG-007 AD Phase 2b study in 2027.
• Evaluate expansion strategy in autoimmune and inflammation.

Key Dates

Recommendation

The filing presents compelling Phase 1b/2a clinical data for IMG-007 in atopic dermatitis, demonstrating significant efficacy and a favorable safety profile. The drug's differentiated mechanism (receptor targeting, non-T cell depleting, extended half-life) positions it as a potential best-in-class therapy in a large and underserved market. The proof-of-concept in alopecia areata further de-risks the asset and expands its 'pipeline-in-a-product' potential. With a strong cash runway through 2027 and a Phase 2b study underway, the company appears well-positioned for future value creation, making it an attractive investment for long-term growth.

Keywords

ImageneBio, IMG-007, Atopic Dermatitis, Alopecia Areata, OX40, Monoclonal Antibody, Phase 2b, Clinical Trial, Immunology, Biologics, Eczema, Autoimmune Disease, Dermatology, Drug Development, Biotechnology